Oct 11, 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Aug 08, 2018
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update
Jul 20, 2018
CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
Jun 15, 2018
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
May 30, 2018
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
May 30, 2018
Rigel Appoints Dean Schorno as Chief Financial Officer
May 29, 2018
Rigel Announces Availability of TAVALISSE(TM) (fostamatinib disodium hexahydrate) in the U.S.
May 23, 2018
Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024
Apr 30, 2018
TAVALISSE(TM) (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
Apr 20, 2018
CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
Apr 17, 2018
Rigel Announces FDA Approval of TAVALISSE(TM) (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Apr 12, 2018
Rigel Makes Statement Regarding Website Error
Jan 04, 2018
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Dec 08, 2017
Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
Nov 10, 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Oct 18, 2017
Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Oct 02, 2017
Rigel Provides Update on FDA Review of Fostamatinib for ITP
Sep 14, 2017
CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
Jun 22, 2017
Rigel Announces Oral Presentation of TAVALISSE(TM) (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
Jun 21, 2017
Amgen To Present New Data At 22nd Congress of the European Hematology Association